FDA Flexible Acceptance Of Published Studies For Supplemental NDAs Urged
Executive Summary
Supplemental NDAs that rely on published studies as evidence should be evaluated by FDA with an understanding that the studies may be conducted under less stringent methods than those generally accepted by the agency, the Pharmaceutical Research & Manufacturers of America advised March 27.